Genetix Biotherapeutics, formerly known as Bluebird bio, has officially rebranded, marking a return to its original name from 1992 when it was founded as Genetix Pharmaceuticals. This change represents a new direction for the company, which was once a leader in cell and gene therapy (CGT) development. Bluebird bio was established in 2010, with its name symbolizing renewal and resilience. Under this name, the company achieved significant milestones, including FDA approvals for therapies treating sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. These treatments are marketed as Lyfgenia, Zynteglo, and Skysona, respectively. At its peak, Bluebird bio was valued at $10 billion but faced financial challenges, leading to its acquisition by private investment firms Carlyle and SK Capital Partners for less than $30 million. Now, as Genetix, the company is poised for a fresh start with stronger financial backing and operational capabilities. The new leadership, including CEO David Meek, emphasizes a renewed focus on delivering life-changing genetic therapies with a streamlined approach. The rebranding also comes amid regulatory scrutiny in the CGT sector, following concerns about the safety and cost-effectiveness of gene therapies. Despite recent FDA restrictions on Skysona due to potential blood cancer risks, Genetix remains committed to advancing its pipeline with the support of experienced industry leaders and significant investor funding. The company aims to simplify access to its one-time, long-lasting treatments for patients in need.